Dr. Rick Lindberg, until 2017, was Executive Director and Head of the Centers for Therapeutic Innovation – California (CTI-California) at Pfizer. As the Head of CTI-California, Rick was responsible for research sites in San Francisco and San Diego that worked with west coast and Australian universities in intimate and innovative collaborations. He led an effort to identify new drug discovery programs and managed a portfolio designed to quickly translate academic science into clinical candidates and Phase 1 clinical trials. As part of the CTI leadership team he reviewed over a thousand academic proposals and selected over thirty projects that resulted in many clinical candidates either heading to or in clinical trials. Before joining Pfizer in 2011, Rick was at Amgen for 19 years, lastly as Executive Director in Discovery Research, directing drug discovery efforts for several metabolic disorders. He also served as a member of the Scientific Advisory Board for Amgen Ventures and as a member of the General Medicine Therapeutic Area Strategic Committee. Before working in metabolic disorders, Rick made significant contributions to the tyrosine kinase and signal transduction fields at Amgen, and prior to that at the Salk Institute of Biology while in the Laboratory of Tony Hunter. He has co-authored over seventy scientific articles and patents, including ten book chapters and review articles. Rick holds a BS in Zoology and a MS in Physiology from Washington State University and a PhD in Biology from University of California, San Diego.
Dr. Rick Lindberg, until 2017, was Executive Director and Head of the Centers for Therapeutic Innovation – California (CTI-California) at Pfizer. As the Head of CTI-California, Rick was responsible for research sites in San Francisco and San Diego that worked with west coast and Australian universities in intimate and innovative collaborations. He led an effort to identify new drug discovery programs and managed a portfolio designed to quickly translate academic science into clinical candidates and Phase 1 clinical trials. As part of the CTI leadership team he reviewed over a thousand academic proposals and selected over thirty projects that resulted in many clinical candidates either heading to or in clinical trials. Before joining Pfizer in 2011, Rick was at Amgen for 19 years, lastly as Executive Director in Discovery Research, directing drug discovery efforts for several metabolic disorders. He also served as a member of the Scientific Advisory Board for Amgen Ventures and as a member of the General Medicine Therapeutic Area Strategic Committee. Before working in metabolic disorders, Rick made significant contributions to the tyrosine kinase and signal transduction fields at Amgen, and prior to that at the Salk Institute of Biology while in the Laboratory of Tony Hunter. He has co-authored over seventy scientific articles and patents, including ten book chapters and review articles. Rick holds a BS in Zoology and a MS in Physiology from Washington State University and a PhD in Biology from University of California, San Diego.
Tom Boone has more than 34 years of accomplishments in the discovery and development of protein therapeutics. Tom worked at Amgen for 28 years and served in positions of increasing responsibility in growing Amgen Protein Sciences to an organization of over 300 researchers across five different sites while maintaining a long tradition of industry excellence. His career at Amgen began in 1981 as a bench scientist with the isolation and cDNA cloning of novel cytokines and growth factors including G-CSF. He was also responsible for purifying many of Amgen’s recombinant proteins. Tom’s responsibilities grew from Scientist to Director and he developed proprietary processes used to produce recombinant G-CSF and other therapeutic candidates for clinical applications. His continuing success led to leadership of all research protein technologies, and the evolution of Protein Sciences as an independent organization. Tom was the first Vice President of Amgen Protein Science and his teams were responsible for the majority of the current Amgen product portfolio and late stage clinical programs. Tom was the lead scientist in the development of Nplate®, a treatment of thrombocytopenia. His critical role in the discovery and process development of G-CSF (Neupogen) is widely recognized. Tom has recently helped start several companies and has helped them license in clinical stage molecules. He is also currently a consultant or scientific advisor for more than 20 companies.
Tom Boone has more than 34 years of accomplishments in the discovery and development of protein therapeutics. Tom worked at Amgen for 28 years and served in positions of increasing responsibility in growing Amgen Protein Sciences to an organization of over 300 researchers across five different sites while maintaining a long tradition of industry excellence. His career at Amgen began in 1981 as a bench scientist with the isolation and cDNA cloning of novel cytokines and growth factors including G-CSF. He was also responsible for purifying many of Amgen’s recombinant proteins. Tom’s responsibilities grew from Scientist to Director and he developed proprietary processes used to produce recombinant G-CSF and other therapeutic candidates for clinical applications. His continuing success led to leadership of all research protein technologies, and the evolution of Protein Sciences as an independent organization. Tom was the first Vice President of Amgen Protein Science and his teams were responsible for the majority of the current Amgen product portfolio and late stage clinical programs. Tom was the lead scientist in the development of Nplate®, a treatment of thrombocytopenia. His critical role in the discovery and process development of G-CSF (Neupogen) is widely recognized. Tom has recently helped start several companies and has helped them license in clinical stage molecules. He is also currently a consultant or scientific advisor for more than 20 companies.
Bill Murray received his Ph.D. in Chemical Biology at the State University of New York at Stony Brook. After a Post Doctoral Fellowship in Chemistry at MIT, he joined Johnson and Johnson in 1980 as a synthetic organic chemist. He has spent most of his career in drug discovery and development chemistry. During his career at J&J, Bill held positions of increasing responsibility in medicinal chemistry and chemical and pharmaceutical development. He has worked in numerous therapeutic areas including inflammation, cardiovascular, hematology, oncology, metabolic disease and urology. He helped design and establish J&J’s La Jolla facility as a fully integrated drug discovery and early development site in the late 1990’s and was the initial chemistry head for that site. Bill has led J&J’s east coast chemistry effort since 1998, and has been vice president of chemistry since 2001. In addition to his discovery chemistry responsibilities, in 2003 and 2004 he led the Chemical and Pharmaceutical Development group for J&J’s early development effort. Bill played a key role in the acquisition and integration of 3DP Pharmaceuticals in 2003 and the acquisition and integration of TransForm Pharmaceuticals in 2005. In addition to his other responsibilities, he served as the Chief Operating Officer of TransForm during their initial year under J&J’s umbrella. With the reorganization of J&J Research and Early Development in 2009, Bill assumed a new role as the chemistry vice president for the Research Capabilities Organization. With the more recent distribution of chemistry into the 5 therapeutic areas in 2011, Bill assumed the role of Chemistry Head for the Cardiovascular and Metabolic Diseases Therapeutic Area. Bill is author of over 100 refereed publications and inventor on over 50 issued U.S. patents. He has served on the advisory boards of a number of academic institutions focused on chemistry, medicinal chemistry and chemical biology. He has also given numerous invited lectures in the areas of Synthetic Organic, Pharmaceutical, Medicinal Chemistry and more recently, outsourcing strategies in Asia. Bill retired from Janssen in 2016 and presently is a consultant to the bioharmaceutical Industry and various non-profits.
Bill Murray received his Ph.D. in Chemical Biology at the State University of New York at Stony Brook. After a Post Doctoral Fellowship in Chemistry at MIT, he joined Johnson and Johnson in 1980 as a synthetic organic chemist. He has spent most of his career in drug discovery and development chemistry. During his career at J&J, Bill held positions of increasing responsibility in medicinal chemistry and chemical and pharmaceutical development. He has worked in numerous therapeutic areas including inflammation, cardiovascular, hematology, oncology, metabolic disease and urology. He helped design and establish J&J’s La Jolla facility as a fully integrated drug discovery and early development site in the late 1990’s and was the initial chemistry head for that site. Bill has led J&J’s east coast chemistry effort since 1998, and has been vice president of chemistry since 2001. In addition to his discovery chemistry responsibilities, in 2003 and 2004 he led the Chemical and Pharmaceutical Development group for J&J’s early development effort. Bill played a key role in the acquisition and integration of 3DP Pharmaceuticals in 2003 and the acquisition and integration of TransForm Pharmaceuticals in 2005. In addition to his other responsibilities, he served as the Chief Operating Officer of TransForm during their initial year under J&J’s umbrella. With the reorganization of J&J Research and Early Development in 2009, Bill assumed a new role as the chemistry vice president for the Research Capabilities Organization. With the more recent distribution of chemistry into the 5 therapeutic areas in 2011, Bill assumed the role of Chemistry Head for the Cardiovascular and Metabolic Diseases Therapeutic Area. Bill is author of over 100 refereed publications and inventor on over 50 issued U.S. patents. He has served on the advisory boards of a number of academic institutions focused on chemistry, medicinal chemistry and chemical biology. He has also given numerous invited lectures in the areas of Synthetic Organic, Pharmaceutical, Medicinal Chemistry and more recently, outsourcing strategies in Asia. Bill retired from Janssen in 2016 and presently is a consultant to the bioharmaceutical Industry and various non-profits.
